WESTMINSTER, Colo., USA (March 23, 2012) – Surefire Medical, Inc., a Colorado-based medical device company, announced today that the 200th procedure using the Surefire Infusion System was performed.

The company launched the Surefire Infusion System in August 2011 in the United States. To date, the Surefire system has been used in 52 key high-volume hospitals, primarily in interventional procedures aimed at treating liver and kidney cancer.

“Since our U.S. launch last summer, Surefire Medical has been committed to delivering hospitals and physicians our product, which is different than what is currently available in treating patients with cancer because of the unique expandable tip,” said Jim Chomas, CEO of Surefire Medical. “By reaching this significant milestone, we have been able to provide physicians with a novel technology that is designed to improve efficiency in their infusion procedures.”

Among the hospitals currently using the Surefire Infusion System is the University of California at San Diego Medical Center (UCSD), a U.S. News and World Report nationally ranked hospital for cancer treatment. Physicians at UCSD are now using the Surefire system as another option in their interventional oncology practice.

“After using the Surefire Infusion System during infusion procedures, I can see how it can potentially improve on patient outcomes both with respect to safety profile and improved tumor control,” said Steven Rose, M.D. at UCSD. “As a leader in cancer treatment, we are always looking for cutting-edge technologies like the Surefire device. After carefully documenting our experience over the past six months, I believe that this technology is potentially game changing and is a powerful tool for interventional radiologists.”

Achievement

Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.